Biocept Akcie

Biocept EPS

Delisted

Zisk na akcii (EPS) společnosti Biocept (BIOC) k datu 4. 8. 2026 je -1,88 USD. V předchozím roce byl Zisk na akcii (EPS) -0,17 USD — změna o 1 021,56 % (nižší).

EPS

-1,88USD

YoY

1 021,56%

Poslední aktualizace:

Zisk na akcii (EPS) společnosti Biocept je 2026 -1,88 USD. Zisk na akcii (EPS) společnosti Biocept byl 2025 -0,17 USD. Klesá tak o 1 021,56% nižší než v předchozím roce.
Access this data via the Eulerpool API

Biocept Analýza akcií

Co dělá Biocept? Biocept Inc is a biotechnology company based in San Diego, California. It was founded in 1997 by Michael W. Nall, an experienced entrepreneur in the field of medical diagnostics and cancer research. Biocept specializes in the development of diagnostic tests and platforms aimed at the rapid and precise identification of cancer cells in the human body. The business model of Biocept focuses on the development of cancer diagnostic tests and selling them to medical labs, physician offices, and hospitals. The company offers a range of different diagnostic products that specialize in various types and stages of cancer. One of Biocept's most important products is a liquid biopsy test that allows medical professionals to quickly and effectively detect cancer cells in patients' blood. This test is particularly significant as it enables doctors to detect cancer at an early stage, thus improving treatment options and increasing the cure rate. Additionally, Biocept offers a variety of tests targeting specific types of cancer such as breast, lung, and prostate cancer. These tests are based on the analysis of tumor DNA extracted from tumor cells in biopsies or liquid biopsies. By accurately analyzing this DNA, medical professionals can determine the specific type and stage of the cancer, thus recommending the best treatment option. In order to expand its range of diagnostic products, Biocept has also entered into partnerships with other companies and research institutions in recent years. For example, in 2017, the company entered into a collaboration with Massachusetts General Hospital to develop a new panel of liquid biopsy tests specializing in the identification of cancer cells in various tissues and organs. Biocept has experienced strong growth in recent years, and its products are now sold in a variety of countries worldwide. The company works closely with medical professionals and research institutions to continuously improve its diagnostic products and develop new tests tailored to the needs of patients with cancer. The output isn't a question, so there is no answer needed. Biocept je jednou z nejoblíbenějších společností na Eulerpool.com.

Často kladené otázky ohledně akcií Biocept

Zisk na akcii (EPS) společnosti Biocept činí -1,88 USD v roce 2026.

Zisk na akcii (EPS) společnosti Biocept se změnilo z -0,17 USD na -1,88 USD, což představuje změnu o 1 021,56 %. Hodnota je nižší než v předchozím roce.

Na Eulerpool najdete úplný historický vývoj Zisk na akcii (EPS) Biocept od roku 2006 – s ročními hodnotami, grafy a podrobnou analýzou.

Zisk na akcii měří část zisku společnosti připadající na každou vydanou akcii a je klíčovou metrikou pro hodnocení ziskovosti společnosti na základě akcie.

EPS = Čistý zisk / Počet vydaných akcií

Access this data via the Eulerpool API

Výkaz zisku a ztráty — Biocept

Všechny klíčové ukazatele — Biocept